NCT05308927View on ClinicalTrials.gov

French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome

Enrolling by invitationOBSERVATIONAL
Enrollment

221

Participants

Timeline

Start Date

March 16, 2022

Primary Completion Date

March 17, 2028

Study Completion Date

March 17, 2028

Conditions
Noonan Syndrome
Interventions
DRUG

Norditropin

Patients will be treated with commercially available Norditropin® according to routine clinical practice at the discretion of the treating physician.

Trial Locations (3)

31059

Hopital Des Enfants-2, Toulouse

49033

Centre Hospitalier Universitaire D'Angers-2, Angers

94275

Ap-Hp-Hopital de Bicetre-2, Le Kremlin-Bicêtre

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT05308927 - French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome | Biotech Hunter | Biotech Hunter